FDA Grants Second Breakthrough Therapy Designation for DT120 in Major Depressive Disorder
DFTX has more than doubled off its 52-week low of $8.773 on light trading volume (0.4× avg).
Summary
Definium Therapeutics announced FDA Breakthrough Therapy designation for DT120 ODT in major depressive disorder, the program's second such designation after GAD, supported by strong Phase 3 Emerge efficacy data.
Key Events · Product Development and Regulatory · DFTX
-
FDA Breakthrough Designation in MDD
FDA granted Breakthrough Therapy designation for DT120 ODT in major depressive disorder, the second such designation for the program after GAD.
-
Phase 3 Emerge Efficacy Data
Designation supported by Phase 3 Emerge results showing a statistically significant 8.1-point placebo-adjusted MADRS improvement at Week 6 (p<0.0001) with durable efficacy through Week 12.
-
Regulatory Pathway Acceleration
Breakthrough designation provides more intensive FDA guidance and potential for expedited development and review, shortening the path to market for a lead asset in a large indication.
-
Commercial Opportunity
MDD affects over 21 million U.S. adults annually with fewer than one-third of patients reaching remission on first-line treatments, representing significant unmet need.
Analysis · DFTX · Life Sciences
The FDA has granted Breakthrough Therapy designation to DT120 ODT for major depressive disorder, the second such designation for the program after GAD. This regulatory milestone follows the positive Phase 3 Emerge results and signals the FDA's view that DT120 may offer substantial improvement over available therapies for a condition affecting over 21 million U.S. adults. Breakthrough designation provides more intensive FDA guidance and the potential for expedited development and review, which can meaningfully shorten the path to market for a lead asset in a large commercial indication.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DFTX was trading at $39.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $8.77 to $49.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.